

1 **SARS-CoV-2 and human milk: what is the evidence?**

2 Kimberly A. Lackey,<sup>1,8</sup> Ryan M. Pace,<sup>1,8</sup> Janet E. Williams,<sup>2</sup> Lars Bode,<sup>3</sup> Sharon M. Donovan,<sup>4</sup> Kirsi M.

3 Järvinen,<sup>5</sup> Antti E. Seppo,<sup>5</sup> Daniel J. Raiten,<sup>6</sup> Courtney L. Meehan,<sup>7</sup> Mark A. McGuire,<sup>2</sup>

4 Michelle K. McGuire<sup>1</sup>

5 <sup>1</sup>Margaret Ritchie School of Family and Consumer Sciences, University of Idaho, Moscow, ID, USA

6 <sup>2</sup>Department of Animal and Veterinary Sciences, University of Idaho, Moscow, ID, USA

7 <sup>3</sup>Department of Pediatrics and Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research  
8 Excellence (MOMI CORE), University of California, San Diego, La Jolla, CA, USA

9 <sup>4</sup>Department of Food Science and Human Nutrition and Institute of Genomic Biology, University of  
10 Illinois, Urbana, IL USA

11 <sup>5</sup>Department of Pediatrics, Division of Allergy and Immunology, University of Rochester School of  
12 Medicine and Dentistry, Rochester, NY, USA

13 <sup>6</sup>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National  
14 Institutes of Health (NIH), Bethesda, MD, USA

15 <sup>7</sup>Department of Anthropology, Washington State University, Pullman, WA, USA

16 <sup>8</sup>Corresponding authors: kimberlyl@uidaho.edu and rmpace@uidaho.edu

17 **ABSTRACT**

18 The novel coronavirus SARS-CoV-2 has emerged as one of the most compelling public health challenges  
19 of our time. To address the myriad issues generated by this pandemic, an interdisciplinary breadth of  
20 research, clinical, and public health communities have rapidly engaged to find answers and solutions.  
21 One area of active inquiry is understanding the mode(s) of SARS-CoV-2 transmission. While respiratory  
22 droplets are a known mechanism of transmission, other mechanisms are possible. Of particular  
23 importance to global health is the possibility of vertical transmission from infected mothers to infants  
24 through breastfeeding or consumption of human milk. However, there is limited published literature  
25 related to vertical transmission of any human coronavirus (including SARS-CoV-2) via human milk and/or  
26 breastfeeding. There is a single study providing some evidence of vertical transmission of human  
27 coronavirus 229E, a single study evaluating presence of SARS-CoV in human milk (it was negative), and  
28 no published data on MERS-CoV and human milk. There are 9 case studies of human milk tested for  
29 SARS-CoV-2; none detected the virus. Importantly, none of the published studies on coronaviruses and  
30 human milk report validation of their analytical methods for use in human milk. These reports are  
31 evaluated here, and their implications related to the possibility of vertical transmission of coronaviruses  
32 (in particular, SARS-CoV-2) during breastfeeding are discussed.

## 33 INTRODUCTION

34 The global pandemic caused by the SARS-CoV-2 virus is one of the most compelling and  
35 concerning global health crises of our time. Fortunately, this pandemic has rapidly engendered a  
36 mobilization of the full range of expertise represented by research, clinical, and public health experts.  
37 While our understanding of the biology, clinical implications, and strategies for mitigation continues to  
38 evolve, one issue that has received limited attention is the implication of this pandemic for infant  
39 feeding practices. This lack of attention has resulted in mixed messages regarding guidance about  
40 optimal infant feeding practices<sup>1,2</sup> and a consequent lack of confidence about the best approaches to  
41 infant feeding in the face of this growing pandemic.

42 Several issues related to this topic demand immediate attention, the first and foremost of these  
43 being whether or not the virus is present in human milk. Of particular interest in this context are 1) the  
44 potential role that breastfeeding could play in vertical transmission of SARS-CoV-2 from women to  
45 infants via human milk; and 2) the potential protective effects of targeted antibodies and other  
46 immunoprotective components in human milk against COVID-19. The goal of this review is to evaluate  
47 the published evidence regarding the presence of this and other human coronaviruses in human milk.

## 48 METHODS

### 49 *Search strategy and selection criteria*

50 We used both Google Scholar and PubMed to identify relevant literature published as of April 4,  
51 2020. Because some of the reports relating to SARS-CoV-2 have not yet been published in refereed  
52 journals (i.e., gray literature), we also used a general Google search and a search of preprint servers  
53 bioRxiv and medRxiv. The list of search terms used can be found in **Table 1**. Any research in which  
54 human milk was collected and tested for a human coronavirus was included in this review.

## 55 RESULTS

### 56 *Overview of vertical transmission of viruses (other than coronaviruses) via human milk*

57 It is well established that viral transmission through human milk can occur.<sup>3,4</sup> Notable examples  
58 include human immunodeficiency virus (HIV),<sup>5,6</sup> cytomegalovirus (CMV),<sup>7</sup> and human T-cell lymphotropic  
59 virus type 1 (HTLV-1).<sup>8</sup> Perhaps the most prominent example of mother-to-child viral transmission via  
60 breastfeeding is HIV, where higher maternal milk and serum viral loads are associated with an increased  
61 risk of transmission.<sup>9-11</sup> The risk of postnatal infection for breastfed infants of HIV+ mothers is ~10-20%  
62 over the first 2 years of life.<sup>12,13</sup> However, compared to mixed feeding, exclusive breastfeeding is  
63 associated with lower risk of transmission of HIV infection to infants.<sup>14,15</sup> In many high-income nations,  
64 breastfeeding is contraindicated in the case of maternal HIV infection.<sup>16,17</sup> However, in low-and-middle-  
65 income nations, infant mortality from malnutrition and infectious disease may outweigh the risk of  
66 acquiring HIV.<sup>16,18</sup>

67 With respect to CMV, it is estimated that ~60-70% of breastfed infants of CMV-seropositive  
68 infants become infected with CMV.<sup>19,20</sup> The risk of CMV infection in neonates is highest in preterm or  
69 very low birthweight (<1500 g) infants;<sup>21,22</sup> in a small percentage of infections, infants develop a severe  
70 complication known as CMV sepsis-like syndrome, which can be fatal.<sup>23</sup> Nonetheless, breastfeeding is  
71 not contraindicated in CMV-seropositive women with healthy, term infants.<sup>16,24,25</sup>

72 For HTLV-1, breastfeeding is considered the major route of infection for infants.<sup>26</sup> HTLV-1  
73 infection is lifelong, and while most infected individuals remain asymptomatic, ~10% develop severe  
74 disease, including adult T-cell leukemia, a highly aggressive and usually fatal malignancy.<sup>27</sup> Some  
75 organizations and agencies list maternal HTLV-1 as a contraindication for breastfeeding,<sup>16,28</sup> while  
76 others do not.<sup>25</sup>

### 77 ***Human coronaviruses and their vertical transmission***

78 Human coronaviruses are enveloped, positive-sense, single-stranded RNA viruses first described  
79 in 1965.<sup>29</sup> There are 7 identified strains known to infect humans. Four of the strains (alphacoronaviruses  
80 229E, NL63, and OC43; betacoronavirus HKU1) are ubiquitous in humans and cause the common cold.

81 There is limited evidence that one of these (229E) may be vertically transmitted from mothers to infants,  
82 although the mechanism remains unclear.<sup>30</sup> The presence of 229E in neonatal gastric samples suggests  
83 that one possible mechanism for infection is through human milk, although this study<sup>30</sup> did not  
84 specifically evaluate the presence of 229E in human milk.

#### 85 **SARS-CoV**

86 In addition to those that cause the common cold, more virulent strains of human coronaviruses have  
87 emerged zoonotically since the early 2000s, the first being SARS-CoV in 2003. The first reports of SARS-  
88 CoV were from China, although the disease (severe acute respiratory syndrome, SARS) quickly spread  
89 globally. SARS is clinically manifested by fever, dry cough, headache, muscle aches, and difficulty  
90 breathing. No treatment exists except supportive care, but there have been no reports of SARS-CoV  
91 transmission since 2004. The case fatality rate of SARS is estimated at 10%.<sup>31</sup>

92 Currently, there is one report in which human milk was tested for SARS-CoV,<sup>32</sup> and two reports  
93 of human milk being tested for SARS-CoV antibodies.<sup>32,33</sup> The former is a case study of a woman infected  
94 during the second trimester of pregnancy (19 wk). A single milk sample was collected 131 days after the  
95 onset of symptoms, but no additional detail on the collection methodologies was provided. Milk was  
96 submitted to the US Centers for Disease Control and Prevention (CDC), where it was analyzed using  
97 reverse transcriptase polymerase chain reaction (RT-PCR) for viral nucleic acids, and enzyme  
98 immunoassay and indirect immunofluorescence to evaluate antibody presence. No additional details on  
99 analytical methods were provided. While no viral RNA was detected, antibodies to SARS-CoV were  
100 identified in the milk. The infant in this study was never tested for SARS-CoV infection. The latter study  
101 was a case report of a 38-yr-old infected in the first trimester of pregnancy (7 wk). She recovered fully  
102 and delivered a healthy male infant at 36 wk of gestation. Milk samples were collected at 12 and 30 d  
103 postpartum and tested for SARS-CoV antibodies; all were negative. No details on the collection or  
104 analysis of the milk were provided. The infant in this study tested negative for SARS-CoV. In both of

105 these studies, it is possible that the women had stopped shedding the virus before the milk samples  
106 were collected, as SARS-CoV shedding in other biological samples typically peaks 12-14 d after the onset  
107 of disease.<sup>34</sup> There are no documented cases of vertical transmission of SARS-CoV between mothers and  
108 infants.<sup>35</sup>

### 109 **MERS-CoV**

110 A related virus, MERS-CoV, emerged in Saudi Arabia in 2012. The disease caused by MERS-CoV, Middle  
111 Eastern respiratory syndrome (MERS), is characterized by severe respiratory illness with symptoms of  
112 fever, cough, and shortness of breath. Like SARS-CoV, MERS-CoV is a betacoronavirus. The case fatality  
113 rate of MERS is 34%.<sup>31</sup> There are no reports, to our knowledge, of the presence or absence of MERS-CoV  
114 in human milk. However, there are reports of the presence of MERS-CoV in the milk of dromedary  
115 camels (*Camelus dromedaries*).<sup>36-38</sup> There is one report of a human likely infected through the  
116 consumption of raw (unpasteurized) camel milk.<sup>39</sup> In camel milk samples spiked with MERS-CoV, viable  
117 virus could still be recovered after 48 hr.<sup>40</sup> These two observations have resulted in recommendations  
118 against consuming raw, unpasteurized camel milk.<sup>41</sup> It is unclear if there is vertical transmission of  
119 MERS-CoV between camelid cows and their calves, and whether infection occurs as a direct result of  
120 lactation/nursing in this species. There are no data on vertical transmission of MERS-CoV between  
121 women and their infants.<sup>35,42</sup>

### 122 **SARS-CoV-2**

123 The novel coronavirus, SARS-CoV-2, was named after SARS-CoV due to its shared sequence homology  
124 (77.9%)<sup>43</sup> and similar clinical characteristics. The first reported cases of SARS-CoV-2 infection emerged in  
125 late 2019 in China. While the case fatality rate for COVID-19 (the disease caused by the SARS-CoV-2  
126 virus) is much lower than those of SARS and MERS at ~2%,<sup>31</sup> the spread of this pathogen has been much  
127 more rapid and extensive.

128           At the time of writing, there were 9 studies that reported direct testing of milk produced by  
129 women who were infected with SARS-CoV-2<sup>44-49</sup> or by women whose infants were infected.<sup>50-52</sup> In total,  
130 23 milk samples produced by 16 women have been tested; all were negative for the presence of the  
131 virus. A description of the relevant characteristics for the women and infants in these studies can be  
132 found in **Table 2**. Six of the nine studies analyzed milk samples collected at birth or shortly thereafter,  
133 reporting only findings in colostrum or colostrum and transitional milk. Those same six studies reported  
134 on the milk produced by women who were infected during the third trimester of pregnancy, while the  
135 other three report findings from milk produced by mothers of infants infected at 1.5, 3, and 6 mo of  
136 age.<sup>50-52</sup> For the infants born to women infected during pregnancy, most were immediately separated  
137 from their mothers post-delivery and were not breastfed for the duration of the period observed in their  
138 respective reports. Twelve of the 16 infants described in these reports were born via cesarean section,  
139 and only one was specified as a vaginal birth. Repeated milk samples were analyzed for 4 of the women,  
140 collected up to 16 days apart. All the studies were conducted in China<sup>44-49,51,52</sup> or Singapore.<sup>50</sup>

141           Wang and colleagues<sup>44</sup> described a healthy, 34-yr-old woman who acquired the infection in  
142 week 40 of pregnancy. She gave birth to a male infant via cesarean section. The infant and his mother  
143 both tested positive for SARS-CoV-2 using pharyngeal swabs within 36 hr of the delivery. The infant was  
144 separated from his mother at delivery and fed formula for the duration of the period described in the  
145 study. The mother's milk was collected at 36 hr postpartum; it tested negative for SARS-CoV-2 via RT-  
146 PCR. No description of the collection or testing methods was provided. The authors stated that they  
147 recommended that the mother not breastfeed, but instead pump milk to avoid mastitis.

148           In another case series from China, Fan and colleagues<sup>45</sup> reported on two women who became  
149 infected during the third trimester of pregnancy. Patient 1 was 34 yr old and in week 37 of gestation at  
150 the time of diagnosis. She delivered a female infant via cesarean section 6 d after testing positive for  
151 SARS-CoV-2 via nasopharyngeal swab. The infant was separated from the mother immediately after

152 delivery, and serial tests of the infant’s nasopharyngeal swabs were negative. A milk sample was  
153 collected within 24 hr of delivery and 16 d later; both were negative for SARS-CoV-2. Patient 2 was 29 yr  
154 old and in week 36 of gestation at the time of diagnosis. Her infant was delivered 5 d after she was  
155 diagnosed via RT-PCR analysis of a nasopharyngeal swab. A single milk sample was collected within 24 hr  
156 of delivery; it tested negative for SARS-CoV-2. The authors of this report did not specify how the sample  
157 was collected, other than “breastmilk was obtained after the first lactation.”

158         Chen and colleague<sup>46</sup> have provided the most extensive report to date, including data on milk  
159 produced by 6 women infected during pregnancy. The women were 26-34 yr-of-age and between 36 wk  
160 2 d and 39 wk 4 d of gestation at diagnosis. The authors did not provide details on the methods used for  
161 milk collection, other than “breastmilk samples from patients with COVID-19 pneumonia were collected  
162 after their first lactation” and that milk was collected following World Health Organization (WHO)  
163 guidelines, but they did not provide a citation for this collection method. All milk tested negative for the  
164 virus, but no information was provided on the methods used for analysis.

165         In a report by Liu et al.,<sup>47</sup> milk produced by two women was tested. One woman was 34 yr old  
166 and at 40 wk gestation tested positive via oropharyngeal swab. Milk was collected and tested from this  
167 women at d 1, 2, and 12 postpartum; all samples were negative. Her male infant was delivered via  
168 cesarean and tested for SARS-CoV-2 via oropharyngeal swab when he was 1 and 7 days old; both swabs  
169 were negative. The other woman was a 30 yr old and delivered an infant vaginally after testing positive  
170 for SARS-CoV-2. Her infant tested negative at birth using an oropharyngeal swab; milk was collected on  
171 d 2 postpartum, it was also negative. Details were provided for neither the methods of collection nor  
172 analysis.

173         In a research letter by Li and colleagues,<sup>48</sup> information was provided related to a 30-yr-old  
174 woman at 35 wk gestation who was positive for SARS-CoV-2 and delivered a male infant via emergency  
175 cesarean section. The infant was tested immediately upon delivery via oropharyngeal swab, which was



176 negative. After delivery, the infant was kept in isolation away from his mother. Milk was collected  
177 immediately after delivery and on d 2 and 3 postpartum; all samples were negative. Again, no  
178 information on the collection or testing methods for the milk sample is available in this report.

179 In another research letter, Dong and colleagues<sup>49</sup> report on a 29-yr-old woman at 34 wk of  
180 gestation who was diagnosed with COVID-19 via nasopharyngeal swab. Nearly a month later, the  
181 woman delivered a female infant via cesarean section. The infant was immediately separated from the  
182 mother with no contact. The infant consistently tested negative for SARS-CoV-2 via nasopharyngeal  
183 swab over the first 12 d of life. However, a blood sample at 2 hr of age was positive for IgG and IgM  
184 antibodies to SARS-CoV-2. A milk sample was collected from the mother at d 6 postpartum; it tested  
185 negative. No information on the collection or testing methods for the milk sample is included in this  
186 report.

187 While the previous reports focused on infected women, there are also three case studies  
188 focused on infected infants. In these studies, milk produced by the infants' mothers was tested for SARS-  
189 CoV-2. The youngest of these infants was reported by Cui and colleagues.<sup>51</sup> After being exposed to  
190 infected family members, the 55-d-old female was admitted to the hospital with symptoms of COVID-19  
191 and diagnosed based on clinical data and exposure history. She was "mixed fed." Her mother's milk was  
192 collected on the first 3 consecutive days of her hospitalization; all milk samples tested negative for SARS-  
193 CoV-2. No information on the collection or testing methods for the milk sample is included in this report.  
194 Yuehua and colleagues<sup>52</sup> reported on a 3-mo-old, breastfed female who was hospitalized and tested via  
195 throat swab for SARS-CoV-2; the swab was positive. A single milk sample was collected from the infant's  
196 mother; it tested negative. The authors provided no information on the collection or testing methods for  
197 the milk. Importantly, this infant developed symptoms of COVID-19 7 d before her parents did. As such,  
198 one possibility is that she was infected first and passed the infection to them. Another case report on a  
199 mature milk sample comes from Singapore.<sup>50</sup> This report is particularly interesting as the infant had no

200 symptoms but was hospitalized and tested because his caregivers were all hospitalized with COVID-19  
201 and there was no one to care for him. The infant was 6 mo old and presumably at least partially human  
202 milk fed as a sample of milk was successfully collected from his mother. Despite being asymptomatic, a  
203 nasopharyngeal swab taken from the infant was positive for SARS-CoV-2. The authors reported that milk  
204 produced by the mother on a single day tested negative for the virus but do not specify how many  
205 samples were taken. This report provided no data on the methods used for the collection and analysis of  
206 these sample(s).

## 207 **DISCUSSION**

208 Despite the devastating clinical manifestations of SARS-CoV, MERS-CoV, and SARS-CoV-2, there remains  
209 much to be learned about their modes of transmission. Respiratory droplets are a documented source  
210 of the virus, but other sources such as human milk may exist. The primary purpose of this review was to  
211 examine the evidence (or lack, thereof) for the vertical transmission of SARS-CoV-2 from mother to  
212 infant via breastfeeding considering what is known about other human coronaviruses.

213         There are currently 9 studies available on SARS-CoV-2 and human milk, collectively  
214 encompassing at least 23 milk samples, all of which tested negative for SARS-CoV-2. There are no  
215 comparable data for MERS, and a single case report for SARS, which yielded a negative result for the  
216 presence of the virus but positive results for antibodies specific to SARS-CoV. There have been no  
217 antibody tests in milk specific to SARS-CoV-2 in any of the reports to date, although one paper reported  
218 on SARS-CoV-2 antibodies in infant serum which were likely transplacental and thus maternal in origin.<sup>49</sup>  
219 This remains a critical area that must be addressed to fully understand the role, if it exists, of  
220 breastfeeding and the feeding of human milk in infant infection.

221         The presence of viable MERS-CoV in camel milk is suggestive of the possibility that SARS-CoV-2  
222 could be present and viable in human milk (or that of other species; to date, the authors are unaware of  
223 any such reports). Notably, Reusken and colleagues<sup>36</sup> reported that milk was not collected from camels

224 aseptically; rather, samples were obtained according to local milking customs. As such, it is possible that  
225 the presence of MERS-CoV in camel milk could be due to contamination from the milker, the calf, or the  
226 environment, rather than milk representing an endogenous source of the virus. However, the limited  
227 data available on all three of these viruses (and human coronaviruses, in general) leave many questions  
228 unanswered with respect to the role, if any, of human milk in vertical transmission of coronaviruses.

229         One possible reason that the RT-PCR results for all the milk samples tested were negative is that  
230 the methods used were neither designed nor validated for human milk. Milk is a complex matrix  
231 containing substantial fat, DNases,<sup>53</sup> and RNases,<sup>54-56</sup> and other PCR inhibitors.<sup>57-59</sup> Thus, validation of  
232 methods using human milk is needed. In addition, other than general statements about the timing of  
233 collection (e.g., “milk was collected after the first lactation”) and brief descriptions of the RT-PCR assays  
234 used for nasal and throat swabs, none of the studies to date has described the methods of collection  
235 and how the milk was handled and stored in any detail. Of note is the fact that commonly used silica  
236 column-based RNA isolation methods are designed for a limited sample volume, and as such are not  
237 suitable for more voluminous liquid samples. In addition, nothing is known about stability of SARS-CoV-2  
238 in human milk and how quickly (or at what temperature) it must be frozen to preserve fidelity.  
239 Information on sample collection, handling, and storage is critical to evaluating whether the negative  
240 results described in these studies could be due to inadequate methods used.

241         Another possibility is that there is low abundance of the virus in human milk, and it has simply  
242 not been captured in the limited samples tested so far. For example, in the report on other human  
243 coronaviruses by Gagneur and colleagues,<sup>30</sup> 159 maternal-infant dyads were tested (including 161  
244 infants, two sets of twins). In this report, 229E was present in both maternal and infant samples in only 2  
245 dyads. Additionally, in the milk of dromedary camels, MERS-CoV appears to be present at very low  
246 abundance.<sup>36</sup> This suggests the possibility that very low viral load in milk might also lead to an inflation  
247 of false negatives.

248 From the limited data on SARS-CoV, it appears that the presence of antibodies in milk could be  
249 influenced by timing of infection, where antibodies to SARS-CoV were detected only in milk produced by  
250 a woman who acquired the infection later in pregnancy. While the methods used to test this milk were  
251 not fully described, this observation could have impacts on the clinical management of infants born to  
252 women diagnosed with COVID-19 during pregnancy and/or lactation. This observation is also supported  
253 by the findings of Dong and colleagues<sup>49</sup> who reported that both IgG and IgM antibodies to SARS-CoV-2  
254 were present in the serum of an infant at 2 hr of age, despite multiple negative RT-PCR tests of  
255 nasopharyngeal swabs over the first days of life. The presence of antibodies at such an early stage of life  
256 could indicate transfer of SARS-CoV-2-specific antibodies from mother to infant during gestation. It is  
257 noteworthy that IgM antibodies<sup>49</sup> present in the serum of SARS-CoV-2 negative infants cannot cross the  
258 placental barrier.<sup>49</sup> Together, these observations suggest infant infection *in utero*, but that the virus may  
259 simply be absent from the upper respiratory tract immediately after birth.

260 Very recent work has demonstrated that, like SARS-CoV and human coronavirus NL63,<sup>60</sup>  
261 angiotensin-converting enzyme 2 (ACE2) is one of the receptors used by SARS-CoV-2 to enter host  
262 cells.<sup>60-62</sup> ACE2 is expressed across many body sites and tissue types, including the oral cavity (e.g.,  
263 tongue and oral mucosa) and in mammary tissue.<sup>63</sup> If mammary epithelial cells express this receptor,  
264 then it follows that viable virus could exist in milk. If it does, then the introduction of virus-containing  
265 human milk could represent a mechanism of entry for SARS-CoV-2 and COVID-19 infection for infants.

266 Another observation worth considering is that in at least one of the reports<sup>52</sup> the infant was  
267 infected and symptomatic 7-8 days prior to the infant's parents. This suggests the possibility that a  
268 "reverse" vertical transmission from infant to mother could occur, a phenomenon which has been  
269 observed for other pathogens, such as HIV<sup>64,65</sup> and Ebola virus.<sup>66</sup> One possible mechanism for maternal  
270 infection in this case is through retrograde flow, where milk and saliva move back into the mammary  
271 gland from the infant's mouth during suckling.<sup>67</sup> While this mechanism is speculative, it represents a

272 possible route whereby an infant could theoretically transfer a pathogen it has encountered in the  
273 environment to the mother. It is also possible that maternal infection could occur through other  
274 mechanisms, such as infant respiratory droplets<sup>68</sup> or via fecal matter.<sup>69</sup>

## 275 **CONCLUSIONS**

276 Human milk is the gold standard for infant feeding. However, confidence with regard to its  
277 safety and best practices around breastfeeding during maternal COVID-19 infection has been  
278 compromised by the lack of evidence as to whether SARS-COV-2 can be vertically transmitted in milk  
279 and/or during breastfeeding. As such, there exists an immediate need to rapidly generate rigorous  
280 evidence for the role (if any) of human milk and breastfeeding in vertical transmission of COVID-19 from  
281 mothers to infants. To accomplish this, validation of analytical methods for the human milk matrix,  
282 viability testing, and evaluation of other immune components in milk will all be critical to this effort,  
283 especially given the known protective effects of breastfeeding in other infant respiratory infections.<sup>70,71</sup>  
284 Substantial interdisciplinary research on this topic is required and should be performed rigorously and  
285 rapidly to best inform policies regarding early feeding choices and clinical management of breastfeeding  
286 mothers infected with SARS-CoV-2 and their infants.

287

## 288 **ACKNOWLEDGEMENTS**

289 The authors acknowledge the generous gift by the Family Larsson-Rosenquist Foundation (FLRF) in  
290 support of UC San Diego's MOMI CORE.

## 291 **AUTHORS CONTRIBUTIONS**

292 KAL, RMP, and JEW performed the literature search. KAL wrote the first draft. All authors read and  
293 contributed to the final manuscript.

## 294 **CONFLICT OF INTEREST STATEMENTS**

295 The authors declare no conflicts of interest.

296 **ROLE OF FUNDING SOURCE**

297 There was no funding source associated with this article.

298 **ETHICS COMMITTEE APPROVAL**

299 Ethics committee approval was not required for this review article.

**Table 1.** Search terms used in combination to identify existing literature reporting the possibility of vertical transmission of coronaviruses from mother to infant during breastfeeding. Google Scholar and PubMed were searched to identify literature published as of April 4, 2020. Preprint servers bioRxiv and medRxiv were also searched to identify preliminary reports that have not undergone the traditional peer-review process.

| <b>General Breastfeeding Terms</b>   | <b>SARS-CoV-2 and General Coronavirus Terms</b>  | <b>SARS-CoV Terms</b>          | <b>MERS-CoV Terms</b> |
|--|--|--------------------------------|-----------------------|
| milk<br>human milk<br>breast<br>breastfeeding<br>breastmilk<br>lactation<br>virus transmission<br>mother-to-child<br>child-to-mother<br>vertical | SARS-CoV-2<br>coronavirus<br>novel coronavirus<br>human coronavirus<br>COVID-19<br>COVID | SARS-CoV<br>SARS<br>SARS-CoV-1 | MERS-CoV<br>MERS      |

**Table 2.** Characteristics of women and infants for whom human milk has been sampled and tested for SARS-CoV-2 using RT-PCR.

| <i>Publication</i>         | Subjects (n)   | Location  | Repeated samples | Time postpartum | Maternal age (yr) | Gestational age at time of maternal infection | RT-PCR results | Infant age at the time of infant infection | Infant sex | Delivery mode | Infant breastfed |
|----------------------------|----------------|-----------|------------------|-----------------|-------------------|---|----------------|--|------------|---------------|------------------|
| <i>Wang et al., 2020</i>   | 1              | China     | no               | 36 hr           | 34                | 40 wk   | negative       | NA   | male       | cesarean      | no               |
| <i>Fan et al., 2020</i>    | 2              | China     | yes              | d 1, 17         | 34                | 37 wk   | negative       | NA   | female     | cesarean      | no               |
|                            |                | China     | no               | d 1             | 29                | 36 wk   | negative       | NA   | female     | cesarean      | no               |
| <i>Kam et al., 2020</i>    | 1              | Singapore | no               | 6 mo            | NS                | NS  | negative       | 6 mo                                       | male       | NS            | yes <sup>1</sup> |
| <i>Chen et al., 2020</i>   | 6 <sup>2</sup> | China     | yes              | 55-57 d         | NS                | NS  | negative       | 50 d                                       | female     | NS            | yes              |
|                            |                | China     | no               | d 1             | 27                | 38 wk, 2 d <sup>3</sup>                       | negative       | NA   | NS         | cesarean      | NS               |
|                            |                | China     | no               | d 1             | 26                | 36 wk, 2 d <sup>3</sup>                       | negative       | NA   | NS         | cesarean      | NS               |
|                            |                | China     | no               | d 1             | 26                | 38 wk, 1 d <sup>3</sup>                       | negative       | NA   | NS         | cesarean      | NS               |
|                            |                | China     | no               | d 1             | 26                | 36 wk, 3 d <sup>3</sup>                       | negative       | NA   | NS         | cesarean      | NS               |
|                            |                | China     | no               | d 1             | 28                | 38 wk <sup>3</sup>                            | negative       | NA   | NS         | cesarean      | NS               |
|                            |                | China     | no               | d 1             | 34                | 39 wk, 4 d <sup>3</sup>                       | negative       | NA   | NS         | cesarean      | NS               |
| <i>Liu et al., 2020</i>    | 2 <sup>4</sup> | China     | yes              | d 2, 3, 12      | 34                | 40 wk   | negative       | NA   | male       | cesarean      | no               |
|                            |                | China     | no               | d 2             | 30                | 37 wk   | negative       | NA   | unclear    | vaginal       | NS               |
| <i>Li et al., 2020</i>     | 1              | China     | yes              | d 1, 2, 3       | 30                | 35 wk   | negative       | NA   | male       | cesarean      | NS               |
| <i>Yuehua et al., 2020</i> | 1              | China     | no               | 3 mo            | NS                | NS  | negative       | 3.5 mo                                     | female     | NS            | yes              |
| <i>Dong et al., 2020</i>   | 1              | China     | no               | 6 d             | 29                | 34 wk, 2 d                                    | negative       | NA   | female     | cesarean      | no               |

Abbreviations: NS, not specified; NA, not applicable

<sup>1</sup>The infant's breastfeeding status was not specified in the report, but it is presumed that he was at least partially breastfed as the mother was producing milk at 6 mo postpartum.

<sup>2</sup>Study presented data from 9 women but only had data on the milk produced by 6 women.

<sup>3</sup>Gestational age upon admission.

<sup>4</sup>Study presented data from 3 women but only had data on the milk produced by 2 women.



301 **REFERENCES**

- 302 1 World Health Organization. Clinical management of severe acute respiratory infection (SARI) when  
303 COVID-19 disease is suspected. Interim guidance. 2020; WHO ref: WHO/2019-nCoV/clinical/2020.4
- 304 2 Centers for Disease Control and Prevention. Coronavirus Disease (COVID-19) and Breastfeeding.  
305 2020; Accessed 4-3-2020 from [https://www.cdc.gov/breastfeeding/breastfeeding-special-](https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/covid-19-and-breastfeeding.html)  
306 [circumstances/maternal-or-infant-illnesses/covid-19-and-breastfeeding.html](https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/covid-19-and-breastfeeding.html)
- 307 3 Jones CA. Maternal transmission of infectious pathogens in breast milk. *J Paediatr Child Health*.  
308 2001;**37**(6):576-82. doi: 10.1046/j.1440-1754.2001.00743.x
- 309 4 Lawrence RM, Lawrence RA. Breast milk and infection. *Clin Perinatol*. 2004;**31**(3):501-28. doi:  
310 10.1016/j.clp.2004.03.019
- 311 5 Ziegler JB, Cooper DA, Johnson RO, Gold J. Postnatal transmission of AIDS-associated retrovirus  
312 from mother to infant. *Lancet* 1985; i: 896–8. doi: 10.1016/s0140-6736(85)91673-3
- 313 6 Black RF. Transmission of HIV-1 in the breast-feeding process. *J Am Diet Assoc*. 1996;**96**(3):267-74;  
314 quiz 275-6. doi: 10.1016/S0002-8223(96)00079-X
- 315 7 Stagno S, Cloud GA. Working parents. The impact of day care and breastfeeding on  
316 cytomegalovirus infections in offspring. *Proc. Natl Acad. Sci. USA*. 1994;**91**: 2384–9. doi:  
317 10.1073/pnas.91.7.2384
- 318 8 Boostani R, Sadeghi R, Sabouri A, Ghabeli-Juibary A. Human T-lymphotropic virus type I and  
319 breastfeeding; systematic review and meta-analysis of the literature. *Iran J Neurol*. 2018;**17**(4):174-  
320 179.
- 321 9 Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk,  
322 mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. *J Infect Dis*.  
323 1999;**180**(1):93-8. doi: 10.1086/314854
- 324 10 Willumsen JF, Filteau SM, Coutsoydis A, et al. Breastmilk RNA viral load in HIV-infected South  
325 African women: effects of subclinical mastitis and infant feeding. *AIDS*. 2003;**17**(3):407-14. doi:  
326 10.1097/00002030-200302140-00015
- 327 11 Davis NL, Miller WC, Hudgens MG, et al. Maternal and Breast Milk Viral Load: Impacts of  
328 Adherence on Peri-Partum HIV Infections Averted - the BAN Study. *J Acquir Immune Defic Syndr*.  
329 2016;**73**(5): 572–580. doi: 10.1097/QAI.0000000000001145
- 330 12 Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1  
331 transmission through breastfeeding. *Lancet*. 1992;**340**(8819):585-8. doi: 10.1016/0140-  
332 6736(92)92115-v
- 333 13 Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on  
334 transmission of HIV-1: a randomized clinical trial. *Lancet*. 2001;**357**(9269): 1651–1655.  
335 doi:10.1016/S0140-6736(00)04820-0

- 336 14 Coutsooudis A, Pillay K, Kuhn L, et al. South African Vitamin A Study Group. Method of feeding and  
337 transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study  
338 from Durban, South Africa. *AIDS*. 2001;**15**(3):379-87. doi: 10.1097/00002030-200102160-00011
- 339 15 Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal  
340 HIV-1 transmission and increases HIV-free survival. *AIDS*. 2005;**19**(7):699-708. doi:  
341 10.1097/01.aids.0000166093.16446.c9
- 342 16 Eidelman AI, Schanler RJ, Section on Breastfeeding. American Academy of Pediatrics policy  
343 statement: Breastfeeding and the use of human milk. *Pediatrics*. 2012;**129**(3):e827-e841.
- 344 17 Centers for Disease Control and Prevention. Human Immunodeficiency Virus (HIV). 2020; Accessed  
345 4-3-2020 from [https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-](https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/hiv.html)  
346 [or-infant-illnesses/hiv.html](https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/hiv.html)
- 347 18 World Health Organization, United Nations Children's Fund. Guideline: updates on HIV and infant  
348 feeding: the duration of breastfeeding, and support from health services to improve feeding  
349 practices among mothers living with HIV. Geneva: World Health Organization; 2016.
- 350 19 Dworsky M, Yow M, Stagno S, Pass RF, Alford C. Cytomegalovirus infection of breast milk and  
351 transmission in infancy. *Pediatrics*. 1983;**72**: 295–9.
- 352 20 Minamishima I, Ueda K, Minematsu T, et al. Role of breast milk in acquisition of cytomegalovirus  
353 infection. *Microbiol Immunol*. 1994;**38**(7):549-52. doi: 10.1111/j.1348-0421.1994.tb01821.x
- 354 21 Lanzieri TM, Dollard SC, Josephson CD, Schmid DS, Bialek SR. Breast milk-acquired cytomegalovirus  
355 infection and disease in VLBW and premature infants. *Pediatrics*. 2013;**131**(6):e1937-45. doi:  
356 10.1542/peds.2013-0076.
- 357 22 Hamprecht K, Goelz R. Postnatal Cytomegalovirus Infection Through Human Milk in Preterm  
358 Infants: Transmission, Clinical Presentation, and Prevention. *Clin Perinatol*. 2017;**44**(1):121-130.  
359 doi: 10.1016/j.clp.2016.11.012
- 360 23 Fischer C, Meylan P, Bickle Graz M, et al. Severe postnatally acquired cytomegalovirus infection  
361 presenting with colitis, pneumonitis and sepsis-like syndrome in an extremely low birthweight  
362 infant. *Neonatology*. 2010;**97**(4):339-45. doi: 10.1159/000260137
- 363 24 Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and Congenital CMV Infection.  
364 2019; Accessed 4-3-2020 from <https://www.cdc.gov/cmV/clinical/overview.html>
- 365 25 World Health Organization. Acceptable medical reasons for use of breast-milk substitutes. Geneva:  
366 World Health Organization; 2009.
- 367 26 Moriuchi H, Masuzaki H, Doi H, Katamine S. Mother-to-child transmission of human T-cell  
368 lymphotropic virus type 1. *Pediatr Infect Dis J*. 2013;**32**(2):175-7. doi:  
369 10.1097/INF.0b013e31827efc39
- 370 27 Rosadas C, Taylor GP. Mother-to-Child HTLV-1 Transmission: Unmet Research Needs. *Front*  
371 *Microbiol*. 2019;**10**:999. doi: 10.3389/fmicb.2019.00999

- 372 28 Centers for Disease Control and Prevention. Contraindications to Breastfeeding or Feeding  
373 Expressed Breast Milk to Infants. 2019; Accessed 4-3-2020 from  
374 [https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/contraindications-to-](https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/contraindications-to-breastfeeding.html)  
375 [breastfeeding.html](https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/contraindications-to-breastfeeding.html)
- 376 29 Tyrrell DA, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. *Br Med J*.  
377 1965;**1**(5448):1467-70. doi: 10.1136/bmj.1.5448.146
- 378 30 Gagneur A, Dirson E, Audebert S, et al. Materno-fetal transmission of human coronaviruses: a  
379 prospective pilot study. *Eur J Clin Microbiol Infect Dis*. 2008;**27**(9):863-6. doi: 10.1007/s10096-008-  
380 0505-7.
- 381 31 Mahase E. Coronavirus covid-19 has killed more people than SARS and MERS combined, despite  
382 lower case fatality rate. *BMJ*. 2020;**368**:m641. doi: 10.1136/bmj.m641
- 383 32 Robertson CA, Lowther SA, Birch T, et al. SARS and Pregnancy: A Case Report. *Emerg Infect Dis*.  
384 2004;**10**(2): 345–348. doi: 10.3201/eid1002.030736
- 385 33 Stockman LJ, Lowther SA, Coy K, Jenny Saw J, Parashar UD. SARS during Pregnancy. United States  
386 *Emerg Infect Dis*. 2004;**10**(9): 1689–1690. doi: 10.3201/eid1009.040244
- 387 34 Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with  
388 probable severe acute respiratory syndrome. *Lancet*. 2004;**363**(9422):1699-700. doi:  
389 10.1016/S0140-6736(04)16255-7
- 390 35 Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-  
391 nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus  
392 infections. *Viruses*. 2020;**12**(2). pii: E194. doi: 10.3390/v12020194.
- 393 36 Reusken CB, Farag EA, Jonges M, Godeke GJ, El-Sayed AM, Pas SD, et al. Middle East respiratory  
394 syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to  
395 local customs from dromedary camels, Qatar, April 2014. *Euro Surveill*. 2014;**19**(23). pii: 20829. doi:  
396 10.2807/1560-7917.es2014.19.23.20829
- 397 37 Hemida MG, Elmoslemay A, Al-Hizab F, et al. Dromedary Camels and the Transmission of Middle  
398 East Respiratory Syndrome Coronavirus (MERS-CoV). *Transbound Emerg Dis*. 2017;**64**(2):344-353.  
399 doi: 10.1111/tbed.12401
- 400 38 Conzade R, Grant R, Malik MR, et al. Reported Direct and Indirect Contact with Dromedary Camels  
401 among Laboratory-Confirmed MERS-CoV Cases. *Viruses*. 2018;**10**(8): 425. doi: 10.3390/v10080425
- 402 39 Memish ZA, Cotton M, Meyer B, Watson SJ, Alshafi AJ, Al Rabeeah AA, et al. Human infection with  
403 MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. *Emerg Infect Dis*.  
404 2014;**20**(6): 1012–1015. doi: 10.3201/eid2006.140402
- 405 40 van Doremalen N, Bushmaker T, Karesh WB, Munster VJ. Stability of Middle East respiratory  
406 syndrome coronavirus in milk. *Emerg Infect Dis*. 2014;**20**(7):1263-4. doi: 10.3201/eid2007.140500.

- 407 41 World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). 2016;  
408 Accessed April 3, 2020 from [https://www.who.int/docs/default-source/documents/health-](https://www.who.int/docs/default-source/documents/health-topics/mers/mers-summary-5december2016.pdf?sfvrsn=f061dca9_1)  
409 [topics/mers/mers-summary-5december2016.pdf?sfvrsn=f061dca9\\_1](https://www.who.int/docs/default-source/documents/health-topics/mers/mers-summary-5december2016.pdf?sfvrsn=f061dca9_1)
- 410 42 Jeong SY, Sung SI, Sung J-H, et al. MERS-CoV Infection in a Pregnant Woman in Korea. *J Korean Med*  
411 *Sci.* 2017;**32**(10): 1717–1720. doi: 10.3346/jkms.2017.32.10.1717
- 412 43 Kim J-M, Chung Y-S, Jo HJ, et al. Identification of Coronavirus isolated from a patient in Korea with  
413 COVID-19. *Osong Public Health Res Perspect.* 2020;**11**(1): 3–7. doi: 10.24171/j.phrp.2020.11.1.02
- 414 44 Wang S, Guo L, Chen L, et al. A case report of neonatal COVID-19 infection in China. *Clin Infect Dis.*  
415 2020. pii: ciaa225. doi: 10.1093/cid/ciaa225.
- 416 45 Fan C, Lei D, Fang C, et al. Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We  
417 Worry? *Clin Infect Dis.* 2020. pii: ciaa226. doi: 10.1093/cid/ciaa226.
- 418 46 Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential  
419 of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet.*  
420 2020;**395**(10226):809-815. doi: 10.1016/S0140-6736(20)30360-3.
- 421 47 Liu W, Wang Q, Zhang Q, et al. Coronavirus disease 2019 (COVID-19) during pregnancy: a case  
422 series. *Preprints* 2020, 2020020373.
- 423 48 Li Y, Zhao R, Zheng S, et al. Lack of vertical transmission of severe acute respiratory syndrome  
424 coronavirus 2, China. *Emerg Infect Dis.* 2020. <https://doi.org/10.3201/eid2606.200287>
- 425 49 Dong L, Tian J, He S, et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother  
426 to Her Newborn. *JAMA* 2020. doi:10.1001/jama.2020.4621
- 427 50 Kam KQ, Yung CF, Cui L, et al. A Well Infant with coronavirus disease 2019 (COVID-19) with high  
428 viral load. *Clin Infect Dis.* 2020. pii: ciaa201. doi: 10.1093/cid/ciaa201.
- 429 51 Cui Y, Tian M, Huang D, et al. A 55-Day-Old Female Infant infected with COVID 19: presenting with  
430 pneumonia, liver injury, and heart damage. *J Infect Dis.* 2020. pii: jiaa113. doi:  
431 10.1093/infdis/jiaa113.
- 432 52 Yuehua ZH, Lin DJ, Xiao MF, et al. 2019 novel coronavirus infection in a three-month-old baby.  
433 *Zhonghua Er Ke Za Zhi.* 2020;**58**(3):182-184. doi: 10.3760/cma.j.issn.0578-1310.2020.03.004.
- 434 53 Babina SE, Kanyshkova TG, Buneva VN, Nevinsky GA. Lactoferrin is the major deoxyribonuclease of  
435 human milk. *Biochem.* 2004;**69**(9):1006-15. doi: 10.1023/b:biry.0000043543.21217.b3
- 436 54 McCormick JJ, Larson LJ, Rich MA. RNase inhibition of reverse transcriptase activity in human milk.  
437 *Nature.* 1974;**251**(5477):737-40.
- 438 55 Das MR, Padhy LC, Koshy R, Sirsat SM, Rich MA. Human milk samples from different ethnic groups  
439 contain RNase that inhibits, and plasma membrane that stimulates, reverse transcription. *Nature.*  
440 1976;**262**(5571):802-5.

- 441 56 Ramaswamy H, Swamy CV, Das MR. Purification and characterization of a high molecular weight  
442 ribonuclease from human milk. *J Biol Chem*. 1993;**268**(6):4181-7.
- 443 57 Al-Soud WA, Jönsson LJ, Rådström P. Identification and characterization of immunoglobulin G in  
444 blood as a major inhibitor of diagnostic PCR. *J Clin Microbiol*. 2000;**38**(1):345-50.
- 445 58 Al-Soud WA, Rådström P. Purification and characterization of PCR-inhibitory components in blood  
446 cells. *J Clin Microbiol*. 2001;**39**(2):485-93. doi: 10.1128/JCM.39.2.485-493.2001
- 447 59 Schrader C, Schielke A, Ellerbroek L, Johne R. PCR inhibitors - occurrence, properties and removal. *J*  
448 *Appl Microbiol*. 2012;**113**(5):1014-26. doi: 10.1111/j.1365-2672.2012.05384.x
- 449 60 Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. Human coronavirus NL63  
450 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. *Proc Natl*  
451 *Acad Sci USA*. 2005;**102**(22):7988-93. doi: 10.1073/pnas.0409465102
- 452 61 Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the  
453 SARS coronavirus. *Nature*. 2003;**426**(6965):450-4. doi: 10.1038/nature02145
- 454 62 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-  
455 length human ACE2. *Science*. 2020;**367**(6485):1444-1448. doi: 10.1126/science.abb2762
- 456 63 Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells  
457 of oral mucosa. *Int J Oral Sci*. 2020;**12**(1):8. doi: 10.1038/s41368-020-0074-x.
- 458 64 Belitsky V. Children infect mothers in AIDS outbreak at a Soviet hospital. *Nature*.  
459 1989;**337**(6207):493. doi: 10.1038/337493a0
- 460 65 Little KM, Kilmarx PH, Taylor AW, Rose CE, Rivadeneira ED, Nesheim SR. A review of evidence for  
461 transmission of HIV from children to breastfeeding women and implications for prevention. *Pediatr*  
462 *Infect Dis J*. 2012;**31**(9):938-42. doi: 10.1097/INF.0b013e318261130f
- 463 66 Sissoko D, Keita M, Diallo B, et al. Ebola Virus persistence in breast milk after no reported illness: A  
464 likely source of virus transmission from mother to child. *Clin Infect Dis*. 2017;**64**(4): 513–516. doi:  
465 10.1093/cid/ciw793
- 466 67 Ramsay DT, Kent JC, Owens RA, Hartmann PE. Ultrasound imaging of milk ejection in the breast of  
467 lactating women. *Pediatrics*. 2004;**113**(2):361-7. doi: 10.1542/peds.113.2.361
- 468 68 World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC  
469 precaution recommendations. 2020; Accessed April 3, 2020 from [https://www.who.int/news-](https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations)  
470 [room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-](https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations)  
471 [precaution-recommendations](https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations)
- 472 69 Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for  
473 persistent fecal viral shedding. *Nat Med*. 2020. doi: 10.1038/s41591-020-0817-4

- 474 70 Chantry CJ, Howard CR, Auinger P. Full breastfeeding duration and associated decrease in  
475 respiratory tract infection in US children. *Pediatrics*. 2006;**117**(2):425-32. doi: 10.1542/peds.2004-  
476 2283
- 477 71 Duijts L, Jaddoe VW, Hofman A, Moll HA. Prolonged and exclusive breastfeeding reduces the risk of  
478 infectious diseases in infancy. *Pediatrics*. 2010;**126**(1):e18-25. doi: 10.1542/peds.2008-3256